Alixorexton (INNTooltip International Nonproprietary Name; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia. Alixorexton is being developed by Alkermes As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1.